Cargando…

Variations within 3′-UTR of MDM4 gene contribute to clinical outcomes of advanced non-small cell lung cancer patients following platinum-based chemotherapy

Single-nucleotide polymorphism (SNPs) in microRNA (miRNA)-binding sites may modulate the posttranscriptional regulation of gene expression and explain individual sensitivity to platinum agents. This study aimed to investigate the impact of SNPs located at 3′-untranslated region (UTR) of MDM4 gene, o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yang, Gao, Wen, Ding, Xi, Xu, Wen, Liu, Di, Su, Bo, Sun, Yifeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369965/ https://www.ncbi.nlm.nih.gov/pubmed/27462918 http://dx.doi.org/10.18632/oncotarget.10771

Ejemplares similares

Polymorphisms of CCNB1 Associated With the Clinical Outcomes of Platinum-Based Chemotherapy in Chinese NSCLC Patients
por: Liu, Di, et al.
Publicado: (2017)

A common polymorphism in the 5′ UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy
por: Somers, Joanna, et al.
Publicado: (2015)

Estrogens Counteract Platinum-Chemosensitivity by Modifying the Subcellular Localization of MDM4
por: Lucà, Rossella, et al.
Publicado: (2019)

Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification
por: Daimon, Tatsuaki, et al.
Publicado: (2021)

Regulatory variation within 3’UTR of STAT5A correlates with sudden cardiac death in Chinese populations
por: Yu, Huan, et al.
Publicado: (2021)

Enhanced Efficacy of Neoadjuvant Chemotherapy with Nab-Paclitaxel and Platinum for Locally Advanced Cervical Cancer
por: Yu, Xiao-Li, et al.
Publicado: (2021)

Associations of CXCL1 gene 5’UTR variations with ovarian cancer
por: Guo, Man, et al.
Publicado: (2020)

A prognostic model for platinum‐doublet as second‐line chemotherapy in advanced non‐small‐cell lung cancer patients
por: Mo, Hongnan, et al.
Publicado: (2016)

Spleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemo-Radiotherapy
por: Wen, Shu Wen, et al.
Publicado: (2015)

Genome-wide analysis identify novel germline genetic variations in ADCY1 influencing platinum-based chemotherapy response in non-small cell lung cancer
por: Mao, Chenxue, et al.
Publicado: (2022)

XRCC3 Thr241Met Is Associated with Response to Platinum-Based Chemotherapy but Not Survival in Advanced Non-Small Cell Lung Cancer
por: Qiu, Mantang, et al.
Publicado: (2013)

First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer
por: Shen, Lan, et al.
Publicado: (2020)

The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer
por: Zhang, Jian-Wei, et al.
Publicado: (2014)

The translational response of the human mdm2 gene in HEK293T cells exposed to rapamycin: a role for the 5′-UTRs
por: Genolet, Raphael, et al.
Publicado: (2011)

Editorial Comment to Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification
por: Matsumoto, Takashi, et al.
Publicado: (2021)

The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Song, Ik-Chan, et al.
Publicado: (2015)

Frequency of HLA‑G UTR‑1/UTR‑3/UTR‑7 in women with unexplained recurrent spontaneous abortion
por: Bai, Wei, et al.
Publicado: (2022)

Advance in integrating platinum-based chemotherapy with radiotherapy for locally advanced nasopharyngeal carcinoma
por: Zhu, Fubin, et al.
Publicado: (2023)

SOCS3 protein expression predicts the responses of advanced non-small cell lung cancer patients to platinum-based chemotherapy
por: Zhang, Xiao-Ming, et al.
Publicado: (2023)

Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer
por: Jia, Yijun, et al.
Publicado: (2017)

Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy
por: Yang, Shih-Hung, et al.
Publicado: (2017)

Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
por: Zhu, Yunshu, et al.
Publicado: (2020)

WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients
por: Liu, Di, et al.
Publicado: (2015)

P73 G4C14‐to‐A4T14 polymorphism is associated with survival in advanced non‐small cell lung cancer patients
por: Ge, Lei, et al.
Publicado: (2017)

Association of variations in the CAT and prognosis in lung cancer patients with platinum-based chemotherapy
por: Liu, Jia-Si, et al.
Publicado: (2023)

NANOG as an adverse predictive marker in advanced non–small cell lung cancer treated with platinum-based chemotherapy
por: Chang, Boksoon, et al.
Publicado: (2017)

Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer
por: Furqan, Muhammad, et al.
Publicado: (2022)

The Efficacy and Response Predictors of Platinum-Based Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer
por: Huang, Yuhui, et al.
Publicado: (2020)

Nanocarriers containing platinum compounds for combination chemotherapy
por: Fang, Guihua, et al.
Publicado: (2022)

ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
por: Wang, Xiyong, et al.
Publicado: (2017)

Meta-analysis of P53 expression and sensitivity to platinum-based chemotherapy in patients with non-small cell lung cancer
por: Lin, Sheng, et al.
Publicado: (2021)

DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study
por: Xiao, Zhiwei, et al.
Publicado: (2022)

Combined systemic immune-inflammatory index and prognostic nutritional index predict outcomes in advanced non-small cell lung cancer patients receiving platinum-doublet chemotherapy
por: Fan, Ruiyun, et al.
Publicado: (2023)

The power of immunotherapy plus platinum–based chemotherapy for locally advanced or early stage non-small cell lung cancer
por: Hofman, Paul
Publicado: (2020)

Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Patel, Shetal A., et al.
Publicado: (2021)

Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer
por: Yang, Qian-Yu, et al.
Publicado: (2022)

Impact of Genetic Variation in TLR4 3′UTR on NSCLC Genetic Susceptibility
por: Wu, Hongjiao, et al.
Publicado: (2020)

WISP1 Polymorphisms Contribute to Platinum-Based Chemotherapy Toxicity in Lung Cancer Patients
por: Chen, Juan, et al.
Publicado: (2014)

Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants
por: Xu, Haiyan, et al.
Publicado: (2020)

Genetic 3′UTR variations and clinical factors significantly contribute to survival prediction and clinical response in breast cancer patients
por: Pamuła-Piłat, Jolanta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qo1blj6b5k185tbgh17folfuqn